Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00474552
Status:
TERMINATED
Last Update Posted:
2008-02-18
First Post:
2007-05-15
Brief Title:
Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of SAM-315
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
An Ascending Multiple-Dose Study of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of SAM-315 Administered Orally to Healthy Young Adult and Elderly Subjects
Status:
TERMINATED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary To assess the safety and tolerability of ascending multiple oral doses of SAM-315 an investigational drug in healthy young adult and elderly subjects
Secondary To assess the Pharmacokinetic and Pharmacodynamic profiles of multiple oral doses of SAM-315 in healthy young adult and elderly subjects
Secondary To assess the Pharmacokinetic and Pharmacodynamic profiles of multiple oral doses of SAM-315 in healthy young adult and elderly subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None